Friday , November 15 2019
Home / taiwan / Scientists develop new artificial blood vessels that can re-form the autologous vascular tissue after its implantation | TechNews

Scientists develop new artificial blood vessels that can re-form the autologous vascular tissue after its implantation | TechNews



[ad_1]

Umacyte, an American regenerative medical technology company, has developed a human Acellular vessel (HAV) that uses bioengineering technology, which demonstrates biocompatibility and regenerability in research and is expected to replace synthetic polymerization in the future . Artificial blood vessels made from the material are transplanted.

When you perform hemodialysis, the doctor must create an "arteriovenous fistula" for the patient to connect the vein artery to produce a container with a larger diameter and a higher discharge to transport the blood to the dialysis machine If the vascular disease of the patient is poor. If you can not establish an autologous fistula, your doctor will recommend the implantation of an artificial blood vessel.

However, the maintenance of artificial blood vessels is not easy. To provide better patient options, Humacyte uses smooth muscle cells and 3D proteins to create a preliminary vascular tissue that pushes the fluid after the formation of the blood vessels to simulate the blood pressure that pumpes the human body and The cells The cells are separated from the blood vessels, eliminating proteins that can be recognized by the immune system as foreigners and forming the "free blood vessels of cells."

In clinical trials, Humacyte found 60 patients with dialysis that needed to be implanted with artificial blood vessels, implanted a VHA of 48 cm and 6 mm in diameter in the arm and observed the sample for 4 years. Although the AVV did not have cells at the time of implantation, the team found that HAV gradually filled the different types of cells of the patient after implantation, over time, 13 of them demonstrated that HAV had been transformed into a similar natural blood vessel. The living fabric of multiple layers, even after injuries, can also be repaired.

More importantly, the implantation of HAV did not show signs of healing or inflammatory response compared to artificial blood vessels composed of synthetic polymers in the past. Currently, Humacyte is conducting three trials in the United States, Europe and Israel to evaluate the efficacy and safety of HAV, which is currently working to increase production and expects to produce tens of thousands of supplies per year in the future.

The research has been published in the journal Science Translational Medicine.

(Source of the image: shutterstock)

<! –

-> <! –

->
<! –

->

[ad_2]
Source link